TScan Therapeutics
TScan Therapeutics

TScan Therapeutics

Biotechnology
WebsiteInvestor RelationsSEC
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

$19.5M

Market Cap • 9/14/2026

2018

(8 years)

Founded

2021

(5 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

0,3

P/S

2,7

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

0,5

EPS

—

Market Cap

Market Cap

19,5M

EV

10,2M

EV/Revenue

1,4

EV/EBITDA

-0,1

EV/EBIT

-0,1

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

0%

Total Yield

0%

Payout

0%

Retained Earnings

-563,9M

Profitability

Gross Margin

100%

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

2969,8%

Capex/Revenue

30,4%

Capex/D&A

74,9%

Capex/OCF

-1,9%

SBC/OCF

—

% PPE

36,1%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Revenue 5Y

3,6%

CAGR Op. Income 5Y

29,1%

CAGR Net Income 5Y

28,5%

CAGR EPS 5Y

-50,1%

CAGR OCF 5Y

28%

Leverage

N.D./EBITDA

0,1

Debt/Equity

0%

Current Ratio

3,4

Quick Ratio

3,2

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium